NewsNovo
Merck CEO Rob Davis told CNBC that the company expects to shorten the manufacturing timeline for its personalized cancer vaccine developed with Moderna, currently set at six weeks.
Davis stated that reducing this duration could allow the firms to reach more patients, though he emphasized that the immediate priority is ensuring supply and market readiness before accelerating production.
The vaccine is designed to target specific mutations in individual patient tumors rather than using a generic approach.
This personalized nature makes production complex, as the process spans from sequencing a patient's tumor to delivering the final product to a hospital.
Keep reading